Moderna COVID-19 vaccine retained neutralizing activity against emerging variants identified in UK and South Africa
On Jan. 25, 2021, Moderna announced results from in vitro neutralization studies of sera from individuals vaccinated with…
-
-
Clinical data showed BD antigen test may be more selective in detecting infectious COVID-19 than molecular tests
On Jan. 25, 2021, BD (Becton, Dickinson) announced the publication of a peer-reviewed study that showed BD’s antigen…
-
Humanigen announced BARDA contract and Expansion of CRADA with U.S. Government for COVID-19
On Jan. 22, 2021, Humanigen announced an expansion to the Cooperative Research and Development Agreement (CRADA) that the…
-
Novavax and Government of Canada finalize advance purchase agreement for COVID-19 vaccine
On Jan. 22, 2021, Novavax announced that it had finalized an agreement with the Government of Canada to…
-
Pfizer and BioNTech reached agreement with COVAX for advance purchase of vaccine to combat COVID-19
On Jan. 22, 2021, Pfizer and BioNTech announced an advance purchase agreement with COVAX for up to 40…
-
Full-dose blood thinners decreased need for life support and improved outcome in COVID-19 patients
On Jan. 22, 2021, the NIH announced that in large clinical trial conducted worldwide, full dose anti-coagulation (blood…
-
COVAX announced new agreement, plans for first deliveries
On Jan. 22, 2021, COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for…
-
The US Department of Defense recommended adults 75 and older should seek COVID-19 vaccine
On Jan. 21, 2021, the U.S. Department of Defense (DOD) recommended that adults ages 75 and older should…
-
Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial
On Jan. 21, 2021, Eli Lilly announced that bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19…
-
Moderna announced first participant dosed in phase 1/2 study of COVID-19 vaccine in Japan led by Takeda
On Jan. 21, 2021, Moderna announced that the first participant has been dosed in the Phase 1/2 study…
-
Patients in cancer remission at high risk for severe COVID-19 illness
On Jan. 21, 2021, Penn Medicine reported that patients with inactive cancer and not currently undergoing treatments also…
-
XBiotech candidate True Humanﾙ COVID-19 therapy found to target highly infectious emerging strain
On Jan. 21, 2021, XBiotech announced that its COVID-19 candidate True Humanﾙ antibody therapy may also be used…
-
TGen-NAU study results showed COVID-19 virus triggers antibodies from previous coronavirus infections
On Jan. 19, 2021, the Northern Arizona University and TGen, an affiliate of City of Hope, announced results…
-
ImmunityBio announced phase I trial of COVID-19 vaccine candidate in South Africa as new variants spread
On Jan. 19, 2021, ImmunityBio announced it had received authorization from the South Africa Health Products Regulatory Authority…
-
Cue’s Molecular, point-of-care COVID-19 tests available under HHS and DoD pilot program
On Jan. 19, 2021, Cue Health announced that its molecular, point-of-care COVID-19 Tests were being distributed to five…
-
Heat Biologics commenced manufacturing process for ZVX-60
On Jan. 19, 2021, Heat Biologics announced it had transferred its gp96-based COVID-19 vaccine cell line (“ZVX-60”) to…
-
Pfizer and BioNTech published results of study showing COVID-19 vaccine antibodies neutralized UK strain
On Jan. 19, 2021, Pfizer and BioNTech announced that results from an in vitro study that provided additional…
-
Quest Diagnostics granted CDC contract to sequence COVID-19 gene variants to aid public health response
On Jan. 18, 2021, Quest Diagnostics announced that it has entered into an agreement with the Centers for…
-
Rapid blood test identified COVID-19 patients at high risk of severe disease
On Jan. 15, 2021, scientists at Washington University School of Medicine in St. Louis announced that that a…
-
UW researchers develop tool to equitably distribute limited vaccines
On Jan. 15, 2021, researchers at the University of Wisconsin School of Medicine and Public Health and UW…
-
RECOVERY trial closed recruitment to convalescent plasma treatment for patients hospitalised with COVID-19
On Jan. 15, 2021, Oxford University announced that on advice of the independent Data Monitoring Committee (DMC), recruitment…
-
COVID-19 reduced US life expectancy, especially among Black and Latino populations
On Jan. 14, 2021, researchers from the University of Southern California and Princeton reported that the COVID-19 pandemic,…
-
Cepheid received Health Canada license for SARS-CoV-2, Flu A, Flu B and RSV combination test
On Jan. 14, 2021, Cepheid that Health Canada announced that it had issued Cepheid a medical device license…
-
Twist Bioscience began shipping of synthetic RNA controls for UK variant strain of SARS-CoV-2
On Jan. 14, 2021, Twist Bioscience announced that it had started shipping its new synthetic RNA reference controls,…
-
Innovation Pharma’s Brilacidin for the treatment of COVID-19 received FDA Fast Track Designation
On Jan. 14, 2021, Innovation Pharmaceuticals announced that the FDA had designated as a Fast Track development program…
-
PerkinElmer SARS-CoV-2 RT-PCR assay received FDA EUA for asymptomatic testing
On Jan. 14, 2021, PerkinElmer announced that its PerkinElmerﾮ Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization…
-
Oxford Immunotec’s T-SPOT SARS-CoV-2 test used to measure efficacy of Valneva’s COVID-19 vaccine candidate
On Jan. 13, 2021, Oxford Immunotec announced the start of a collaboration with Valneva whereby it will perform…
-
Mateon announced positive interim results from its ARTI-19 clinical trial evaluating ARTIVeda against COVID-19
On Jan. 13, 2021, Mateon Therapeutics reported positive interim results from its ARTI-19 clinical trial evaluating ARTIVedaTM against…
-
The USDA confirmed COVID-19 in gorillas at San Diego Zoo Safari Park
On Jan. 13, 2021, the USDAﾒs (USDA) National Veterinary Services Laboratories announced confirmation of SARS-CoV-2 (the virus that…
-
Alexion updated phase 3 study of ULTOMIRISﾮ (ravulizumab-cwvz) in hospitalized patients with COVID-19
On Jan. 13, 2021, Alexion announced the decision to pause further enrollment in the global Phase 3 study…
